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Background.Itiscurrentlyrecommendedthatdietofpregnantmotherscontain200–300mgDHA/day.Aim.Todeterminewhether
DHA supplementation during pregnancy and lactation aﬀects infants’ immune response. Methods.6 0w o m e ni n≥3rd pregnancy
studied; 30 randomly assigned to receive DHA 400mg/day from 12th week gestation until 4 months postpartum. From breast-fed
infants, blood obtained for anti-HBs antibodies, immunoglobulins, lymphocyte subset phenotyping, and intracellular cytokine
production. Results. CD4+ lymphocytes did not diﬀer between groups, but CD4CD45RA/CD4 (na¨ ıve cells) signiﬁcantly higher in
infants in DHA+ group. Proportion of CD4 and CD8 cells producing IFNγ signiﬁcantly lower in DHA+ group, with no diﬀerences
in proportion of IL4-producing cells. Immunoglobulins and anti-HBs levels did not diﬀer between groups. Conclusions. In infants
of mothers receiving DHA supplementation, a higher percentage of CD4 na¨ ıve cells and decreased CD4 and CD8 IFNγ production
is compatible with attenuation of a proinﬂammatory response.
1.Introduction
Breast feeding is believed to confer protection against infec-
tions during infancy. Breast-fed infants have an enhanced
local humoral immune response, resulting in a lower preva-
lence of gastrointestinal and respiratory tract infections than
in formula-fed infants [1, 2]. Exclusive breast feeding for
the ﬁrst few months has also been suggested to be protective
against the development of atopic disease [3]. Immunoglob-
ulins, lymphocytes, proteins like lactoferrin, and lysozyme,
which are present in breast milk, play a speciﬁc immunologic
role. Another component, which may be of pivotal impor-
tance to maturation and function of the immune system,
is the fatty acid pattern of the milk. Human milk contains
long chain polyunsaturated fatty acids (LCPUFA) (20–22
carbons) of both w-3 and w-6 classes which constitute ∼2%
of total fatty acids and which are undetectable in unsupple-
mented formulas prepared from vegetable oils. RBC mem-
brane phospholipids of breast-fed infants have a signiﬁcantly
higher percentage of w-3 fatty acids (FA) and speciﬁcally
a twofold higher level of docosahexanoic acid (DHA) (C22:6
w-3) than infants fed by nonsupplemented formula, with
similar membrane levels of arachidonic acid (AA) (C 20:4
w-6) [4, 5]. The balanced ratio of arachidonic acid-derived
eicosanoids and those derived from w3 fatty acids has been
suggested to play a crucial role in immune modulation
[6–8].
In infants who are breast fed, supply of these fatty acids
is dependent on the maternal diet [9]. The Western diet
contains large amounts of w-6 FA but is relatively low in
w-3 FA. Maternal DHA status depends mainly on intake
of DHA itself as conversion of alpha-linolenic acid (C18:3
w-3), present in nuts and other vegetable oils, into DHA
is low. Levels of maternal DHA decline during pregnancy
and decrease even further when the lactation period is
extended [10]. Maternal DHA levels decline with multiple
pregnancies; levels have been shown to be signiﬁcantly lower
in multiparous compared with primiparous mothers and
when pregnancies are closely spaced. Furthermore, levels of
DHA in breast milk correlate with DHA blood levels [11].2 Mediators of Inﬂammation
ThehighdemandforDHAhaspromptedcurrentrecom-
mendations that during pregnancy and lactation the average
dietary intake of DHA should be 200–300mg per day [12,
13]. Indeed, recent studies have established that the diet of
Western pregnant and lactating women contains only 20%–
60% of the w-3 FA recommended daily intake. In 90% of
the women surveyed, DHA intake was far below the recom-
mended requirement [14, 15].
Previous studies relating to the immune system in in-
fants have compared infants fed human milk with infants
fedeithervLCPUFA-supplementedornonsupplementedfor-
mulas [16, 17]. In pregnant women receiving a DHA+EPA
preparation, from the 22nd gestational week, maternal
blood mRNA levels of Th1 cytokines (IFNγ and IL1) were
decreased, whereas, in cord blood, levels of Th2 cytokines
(IL4 and IL13) were decreased [18]. No studies have exam-
ined the eﬀect of maternal DHA supplementation during
pregnancy and lactation on the infants’ immune system.
We therefore questioned whether DHA supplementation
during pregnancy and lactation, in a population with a
high percentage of multiparous mothers with closely spaced
pregnancies, may aﬀect the humoral and cellular immune
response in infants solely breast-fed up to the age of 4
months.
2.SubjectsandMethods
2.1. Subjects. The mothers of the babies studied belong to an
ultraorthodox religious community; 60 pregnant women,
age 20–35 years, in their ≥3rd pregnancy. 30 women were
randomly assigned to receive DHA 400mg/day (each softgel
capsule containing 100mg DHA, produced by Martek Bio-
sciences Corporation, Solgar, Leonia, NJ, USA). DHA sup-
plementationwastakendailyfromthe12thweekofgestation
and continued until the end of the 4th postpartum month.
MotherswhowerenotassignedtotheDHAsupplementation
group declined intake of placebo capsules on religious
grounds, as the gelatin capsules are not “kosher”, but since
the DHA was regarded by the religious leaders of the comm-
unityasamedication,intakeofDHAcapsuleswaspermitted.
In the DHA-supplementation group, 18 mothers were in
their 3rd-4th pregnancy, 11 were in their 5th–7th pregnancy,
and 1 was in her 8th. In the control group, 17 mothers were
in their 3rd-4th pregnancy, 11 in the 5th–7th, and 2 in the
≥8th pregnancy.
A nutritional intake questionnaire, with an emphasis on
type of cooking oil used, amount and type of ﬁsh, and/or
nuts consumed, was ﬁlled out by all mothers.
Infants were exclusively breast-fed for 4 months. At age
of 4 months, blood was drawn (maximum 5mL of which
2.5mL in EDTA and 2.5mL in heparin) for complete blood
counts (CBC), anti-HBs antibody titers, immunoglobulin
levels, and lymphocyte studies.
2.2. Methods
2.2.1. Anti-HBs Antibodies. Quantitatively determined using
a microparticle enzyme immunoassay 9AxSYMAVSAB,
Abbot Diagnostics, Wiesbaden, Germany.
2.2.2. Immunoglobulin Levels. Quantitative determination of
immunoglobulins (IgA, IgM, IgG) was performed by means
of immunonephelometry using BN ProSpec Systems, Sie-
mens Healthcare Diagnostics, Marburg, Germany.
2.2.3. Lymphocyte Studies
Monoclonal Antibodies. The following monoclonal anti-
bodies were obtained from Immunoquality Products,
Groningen, the Netherlands: anti-CD8, anti-CD45RO, anti-
CD45RA, and anti-CD25. Anti-CD4 and anti-CD6 mAb
were purchased from eBioscience, Inc., San Diego, Calif.
MAbs for the detection of intracytoplasmic cytokines
were obtained from BD Biosciences (San Jose, Calif).
Fastimmune PE-labeled antihuman IL4 was used for the
detectionofIL4,whileFastimmuneFITC-labeledantihuman
interferon-γ (IFNγ) was used for the detection of IFNγ.
Immunoﬂuorescent Staining of Peripheral Blood Lympho-
cyte Subsets. The following peripheral blood lymphocyte
subsets determined by cell surface staining using a ﬂuo-
rescent activated cell sorter: CD4, CD4CD45RA (“na¨ ıve”
T helper cells), CD4CD45RO (“memory”/activated helper
cells), CD8, CD8CD45RA (“na¨ ıve” T suppressor cells),
CD8CD45R0 (“memory”/activated suppressor cells), and
CD16 (NK cells). Whole blood cells, in heparin, were
washed twice in PBS and suspended in PBS containing
0.1% BSA and 0.1% NaN3. Suspensions at a volume of
100μL, were introduced into each test tube and stained
with mAbs. The cells were incubated with either FITC- or
PE-conjugated mAbs for 30min at 4◦C. The mixture of
cells and antibody was incubated for 30min at 4◦C. After
incubation the red blood cells were lysed with FACS lysing
solution (Becton Dickinson). After two incubations of the
blood with NH4CL for 10 minutes at room temperature,
the suspension was centrifuged, the pellet washed twice with
PBS, and cells resuspended in 1% paraformaldehyde and
stored at 4◦C until they were analyzed by ﬂow cytometry
[19].
2.2.4. Cell Activation for Cytokine Production. 0.5mL whole
blood, in heparin, was introduced into disposable polysty-
rene tubes. To 0.5mL blood, 0.5mL RPMI-1640 medium
and 2mM L-glutamine were added. The tissue culture
medium components were purchased from Biological
I n d u s t r i e s ,B e i tH a e m e k ,I s r a e l .F o ra c t i v a t i o nc e l l sw e r e
exposed to mitogens, 25ng PMA and 1.0μg ionomycin.
10μg brefeldin A (BFA) were added to each tube; BFA
inhibits intracellular transport and prevents secretion of the
intracellular cytokines. The suspensions were incubated at
37◦Ci na5 %C O 2 humidiﬁed atmosphere for a 4-hour
incubation.
2.2.5. Intracytoplasmic Immunoﬂuorescent Staining of Cyto-
kines in Activated Cells. For intracytoplasmic immunoﬂuo-
rescent staining, the cells were resuspended in 500μLF A C S
permeabilizing solution, obtained from Becton Dickinson,
and were left for 8–10 minutes at room temperature.Mediators of Inﬂammation 3
Table 1: Characteristics of mothers and infants studied.
DHA-supplemented
group Control group
Mothers
Age (y) 27.7 ± 4.2 27.6 ± 4.6
Pregnancy (no.)
3rd-4th 18 17
5th–7th 11 11
≥8th 1 2
Infants
Birth weight (kg) 3.33 ± 0.4 3.30 ± 0.5
Gestational age (weeks) 40.0 ± 1.6 39.9 ± 0.9
Infectious episodes (no.) 2 (fever/URI) 1 (pertussis)
Birth-4 months
Nutrition Solely breast fed Solely breast fed
Data are mean ± SD, P = n.s.
The cells were washed twice in PBS containing 0.5% BSA
and 0.1% NaN3.2 0μL of ﬂuorescent conjugated mAbs were
added to stain intracytoplasmic cytokines. IgG preparation
of suitable isotypes was used as negative controls [20]. The
cells were incubated for 30 minutes at room temperature,
washed and ﬁxed in a solution of 1% paraformaldehyde
in PBS, and stored at 4◦C until they were analyzed by
ﬂow cytometry. Acquisition and analysis were carried out
in a FACScan ﬂow cytometer (Becton Dickinson) using the
FACScan software program. For each test, 5000–10000 cells
werecollectedandacquired. Becauseof the smallamounts of
blood that could be obtained, these assays were performed in
only 21 infants, in each group.
The study was approved by the Ethics Committee (IRB)
of the Kaplan Medical Center and the Review Board of the
Ministry of Health.
2.3. Statistical Analysis. Statistical analysis for evaluation
of signiﬁcant diﬀerences was performed with the use of
Student’s t test for unpaired data with InStat (GraphPad
Software Inc. San Diego, CA). Results were presented as
mean ± SEM.
3. Results
3.1. Demographic Characteristics. Demographic characteris-
tics of the mothers and infants studied are summarized
in Table 1. Mothers’ age and parity did not diﬀer between
mothers receiving DHA supplementation and the nonsup-
plemented group. Infants’ birth weight, gestational length,
and number of infectious episodes documented until perfor-
manceofimmunology studies, atage4monthsdid notdiﬀer
between groups.
3.2. Anti-HBs Antibodies. 117.9 ± 34.3IU/mL (mean ±
SEM)ininfantsofDHA-supplementedmothersversus111.9
± 56.1IU/mL in thenonsupplemented group (P = n.s).
3.3. Immunoglobulins. I g Al e v e l sw e r e3 3 . 9± 4.22mg%
(mean ± SEM) in the DHA group versus 54.5 ± 15.6 mg% in
controls (P = n.s). IgM levels were 99.7 ± 15.0mg% in the
DHA group versus 91.8 ± 20.8mg% in controls (P = n.s).
IgG levels were 593.6 ± 70.3mg% in the DHA group versus
745.7 ± 162.7mg% in controls (P = n.s).
3.4. Total Lymphocyte Count. Total lymphocyte count did
not diﬀer between the two groups of babies; 6598 ± 450/
mm3 (mean ± SEM) in the babies of supplemented mothers
versus 6900 ± 650/mm3 (mean ± SEM) in controls (P =
n.s).
3.5. Lymphocyte Subsets. In the babies of w3-supplemented
mothers, the percentage of CD4+ lymphocytes did not diﬀer
signiﬁcantly from that of the control group (46.9 ± 1.61
versus 41.0 ± 2.75, P = n.s), but CD8+ lymphocytes
were signiﬁcantly lower (17.7 ± 0.98 versus 21.25 ± 0.09,
P<0.05) (Table 2). Among CD4+ cells, the proportion of
the CD4+CD45RA+ subset, representing na¨ ıve helper cells,
was signiﬁcantly higher in the infants of w3-supplemented
mothers as compared with the control group. The propor-
tion of CD45RA+CD4+ cells constituted 87.23 ± 0.89 of
total CD4 population in the supplemented group versus
79.8 ± 2.95 in controls (P<0.05). The percentage of
memory CD4 cells, CD4+CD45RO+/CD4, did not diﬀer
between the two groups (15.79 ± 1.77 versus 12.80 ±
2.01 (P = n.s)). Of CD8+ cytotoxic suppressor cells,
although the percentage of CD8 cells was lower among
infants of mothers receiving DHA supplementation, the
CD8+CD45RO+/CD8 fraction, representing memory cells,
was higher in the DHA-supplemented group; 34.9 ± 5.9
versus 16.2 ± 5.9 (P<0.05). The sum of the two CD8
fractions, na¨ ıve CD8+ cells (CD8+CD45RA+), and activated
CD8+cells(CD8+CD45RO+)ishigherthan100%,denoting
that a proportion of the cells has stained positive for
both markers, and is a phenomenon observed during the
transition from a na¨ ıve to an activated state. The proportion
of CD16+ lymphocytes did not diﬀer signiﬁcantly between
the two groups (14.92 ± 9.08 versus 14.58 ± 5.51, in DHA-
supplemented and control groups, resp.).
3.6. Cytokine Production. The proportion of CD4+ and of
CD8+ producing IFNγ was signiﬁcantly lower in the DHA-
supplemented group (Table 3). The proportion of IFNγ
producing CD4+ cells was 0.99 ± 0.18% among the DHA-
supplemented group versus 2.68 ± 0.69 among controls
(P = 0.01). Similarly among CD8+ cells, the proportion
of IFNγ producing cells was 0.62 ± 0.13 versus 1.84 ±
0.43, respectively, (P = 0.01). IL4 production in CD4+ and
CD8+ cells was lower in the DHA-supplemented group, but
diﬀerences did not reach statistical signiﬁcance (Table 3).
4. Discussion
The peripheral blood lymphocyte proﬁle of breast-fed
infants of mothers who have received DHA supplementation4 Mediators of Inﬂammation
Table 2: The eﬀect of maternal DHA supplementation on pheno-
type of infants’ peripheral blood lymphocytes.
DHA-supplemented
group
Control
group
CD4+ cells 46.93 ± 1.61 41.02 ± 2.75 P = n.s
CD8+ cells 17.67 ± 0.98 21.25 ± 0.99 P = 0.01
CD45RA+ CD4+
CD4+ 87.23 ± 0.89 79.86 ± 2.95 P<0.05
CD45RO+ CD4+
CD4+ 15.79 ± 1.77 12.80 ± 2.01 P = n.s
CD45RA+ CD8+
CD8+ 94.02 ± 0.85 90.08 ± 1.45 P<0.05
CD45RO+ CD8+
CD8+ 35.51 ± 6.20 16.80 ± 5.42 P<0.05
Data are mean ± SEM, expressed as % of peripheral blood lymphocytes.
Table 3: The eﬀect of maternal DHA supplementation on cytokine
production by infants’ peripheral blood lymphocytes.
DHA-supplemented group Control group
CD4+ IL4+ 0.69 ± 0.12 1.24 ± 0.56 P = n.s
CD8+ IL4+ 0.26 ± 0.07 0.68 ± 0.31 P = n.s
CD4+ IFNγ+0 . 9 9 ± 0.18 2.68 ± 0.61 P = 0.01
CD8+ IFNγ+0 . 6 2 ± 0.13 1.84 ± 0.43 P = 0.01
Data are mean ± SEM, expressed as % of peripheral blood lymphocytes.
during pregnancy and lactation diﬀers from that of breast-
fed infants whose mothers’ diet was not supplemented with
DHA.
Infants in the DHA-supplemented group had a similar
number of CD4 cells as the nonsupplemented group, but
the number of CD8 cells was signiﬁcantly reduced so
that the CD4/CD8 ratio was 2.6 among lymphocytes of
the DHA-supplemented infants as compared with 1.9 in
the nonsupplemented group. Of CD4 cells the fraction
of CD45RA+ cells, representing na¨ ıve helper cells, was
signiﬁcantly higher in the DHA-supplemented group than in
the nonsupplemented group. Although total population of
CD8 cells was lower in DHA-supplemented infants, the pro-
portion of CD8+CD45RO+ activated cells was signiﬁcantly
higher, constituting 35% of CD8 cells as compared with 16%
in the nonsupplemented group. In both CD4 and CD8 cells,
the production of IFNγ was found to be markedly lower in
lymphocytesofthe infants intheDHA-supplementedgroup.
Infants of both groups resided in the same neighborhood
and were likely exposed to similar environmental antigens
and infectious hazards. The diﬀerences in the level of
lymphocyte subsets between the two groups of babies can
therefore not be attributed to a diﬀerent degree of bacterial
or viral exposure.
Field et al. [16] have previously studied the immune
consequences of adding arachidonic acid (ARA) and DHA to
preterm formula-fed infants as compared with human milk-
fed preterm infants. At 42 days of age, the lymphocyte subset
populationininfantsreceivinganLCPUFA-fortiﬁedformula
showed an increase in the proportion of CD4CD45RO+
cells and CD8CD45RO+ cells over that present in peripheral
blood of formula-fed infants, a lymphocyte subset pattern
more consistent with that observed in infants fed human
milk. Activation of IL2, a major proinﬂammatory cytokine,
measured indirectly based on the amount of SIL-2R pro-
duced by peripheral mononuclear cells, was noted to be
lower in LCP-fed infants with levels comparable to those
in human-milk-fed infants. This observed decrease in IL2
activation is in agreement with other studies both in vitro
and in vivo (animals and adults) that have demonstrated
that LCPUFA reduce IL2 production [21]. Production of
TNFα, another proinﬂammatory cytokine, from mononu-
clearcells,hasalsobeenshowntodecreaseinadultsreceiving
LCPUFA [22]. A recent study has demonstrated decreased
release of IFNγ-induced protein from airway epithelial
cells infected with rhinovirus, when incubated with DHA
[23].
In a study conducted in children aged 5–7 years con-
suming a diet with low DHA intake, adding ARA and DHA
(14–21mg/day) for a 7-month period did not lead to any
changes in relative proportion of CD4 and CD8 cells, in non-
stimulated whole blood.
Furthermore, IFNγ production by peripheral blood
mononuclear cells, following exposure to various stimu-
lants/mitogens, did not diﬀer in the LCPUFA-supplemented
group [17]. Another study, in older children aged 8–12
years, reached diﬀerent conclusions regarding the eﬀect
of w-3 FA on cytokine production. In children receiving
300mg ﬁsh oil (+700mg canola oil) per day for 12 weeks,
peripheral blood mononuclear cells incubated in absence
or presence of lipopolysaccharide stimulation exhibited a
nonspeciﬁcenhancementofbothproinﬂammatoryandanti-
inﬂammatory down regulatory cytokine production [24].
Notably, while some in vitro and in vivo studies, in animal
models and adults, have also noted that LCPUFA induce an
increase of TNF, IL1, and IL2 production, others have failed
to show any eﬀect of diﬀerent doses of ﬁsh oil on production
of these cytokines [7, 25–27].
Most studies have assayed the level of cytokines present
in supernatants of isolated peripheral blood mononuclear
cells or lymphocyte cultures. In our study, utilization of a
technique for the intracellular staining of cytokines enabled
us to determine the selective origin of cytokines, whether
from CD4 or CD8 cells.
DHA supplementation did not exert an eﬀect on the
humoral immune response. Infants in both groups did not
diﬀer in levels of immunoglobulins of IgG, IgM, and IgA
class.
Speciﬁc antibody response as reﬂected by measuring the
titerofantibodiestoHBsAgafter2dosesofvaccine(at2days
and at 1 month of age) was similar in both groups.
All infants in our study were exclusively breast fed for the
ﬁrst 4 months of age. As for the diet of the mothers taking
part in the study, they all ate at least 2 servings of ﬁsh per
week, cooked with canola oil, which is rich in w-3 FA, and
added olive oil as salad dressing. A recent consensus state-
ment regarding dietary fat intake for pregnant and lactating
women has concluded that “ the desired average intake of at
least 200mg DHA/day can be reached with the consumptionMediators of Inﬂammation 5
of one to two portions of sea ﬁsh per week” [13]. Thus, their
dietary intake of DHA may be considered as adequate.
Our study is unique in that it questioned whether
additional DHA supplementation to breast-feeding mothers
who are consuming a diet supposedly suﬃcient in DHA
content would aﬀect the immune response of their infants.
DHA supplementation during pregnancy and lactation
did not result in changes in the infants’ humoral immune
response, as assessed by levels of anti-HBs antibodies and
total immunoglobulins, but did aﬀect lymphocyte subset
proﬁle and cytokine production.
A lymphocyte proﬁle with a higher percentage of CD4
na¨ ıve cells and decreased IFNγ production in both CD4
and CD8 cells is likely compatible with attenuation of a
proinﬂammatory response.
Local expression of proinﬂammatory cytokines, particu-
larly IFNγ and TNF, has been shown, in animal models, to
worsen damage as incurred, for example, during ischemic
strokes [28]. Dampening of the proinﬂammatory response
may thus serve to limit tissue damage during infectious and
noninfectious inﬂammatory situations. Yet it is noteworthy
that although interferon-γ is considered to be an important
proinﬂammatory cytokine produced by Th1 lymphocytes
and by natural killer cells, mediating both innate and
adaptive immune response, recent observations indicate that
IFNγ may exert suppression of the immune response and
may play a role in the induction of tolerance.
IFNγ has been shown to modulate T-cell activation by
reducing T-cell proliferation and survival and by increasing
the number of regulatory T cells (Foxp3+ Treg cells) [29, 30].
IFNγ also stimulates the expression of inhibitory B7 family
molecules, which in turn may abate the production of Th1
T cells [31]. Thus, the immunological consequences of the
striking decrease in IFNγ production in both CD4 and CD8
cells cannot be simply predicted. As for the observed higher
percentage of cytotoxic activated CD8 cells, these may play a
facilitatory role in encountering of viral infections.
The clinical implications of the changes observed are as
yet speculative, and whether supplementation of DHA to
breast-feeding mothers confers an advantage to their infants
remains to be elucidated.
Authors’ Contribution
E. Granot, Principal Investigator, helped in initiating and
designing of project, analysis of data, and writing of
manuscript and took the responsibility for its ﬁnal content.
E. Jakobovich, Study Coordinator, helped in the clinical
followupofmothersandinfantsanddatacollection.R.Rabi-
nowitz and P. Levy performed lymphocyte studies and con-
tributed to analysis of data. M. Schlesinger is director of the
laboratory in which lymphocyte studies were performed and
is responsible for planning of lymphocyte studies and analy-
sis of the data. All authors read and approved the ﬁnal paper.
Conﬂict of Interests
The authors have no conﬂict of interests to report.
Acknowledgment
T h es t u d yw a sf u n d e db yag r a n tr e c e i v e df r o mt h eP h i l i p
Morris External Research Program (Philip Morris USA and
Philip Morris International Inc.). DHA capsules were a kind
gift from the Solgar company, Israel.
References
[1] A.K.KoutrasandV.J.Vigorita,“Fecalsecretoryimmunoglob-
ulin A in breast milk versus formula feeding in early infancy,”
Journal of Pediatric Gastroenterology and Nutrition, vol. 9, no.
1, pp. 58–61, 1989.
[2] H. B. Slade and S. A. Schwartz, “Mucosal immunity: the
immunology of breast milk,” Journal of Allergy and Clinical
Immunology, vol. 80, no. 3, pp. 348–358, 1987.
[3] M. S. Kramer, “Does breast feeding help protect against atopic
disease?” Journal of Pediatrics, vol. 112, no. 2, pp. 181–190,
1988.
[4] M. L. Pita, M. R. Fernandez, C. De-Lucchi et al., “Changes
in the fatty acids pattern of red blood cell phospholipids
induced by type of milk, dietary nucleotide supplementation,
and postnatal age in preterm infants,” Journal of Pediatric
Gastroenterology and Nutrition, vol. 7, no. 5, pp. 740–747,
1988.
[ 5 ]E .G r a n o t ,D .G o l a n ,a n dE .M .B e r r y ,“ B r e a s t - f e da n d
formula-fed infants do not diﬀer in immunocompetent cell
cytokineproductiondespitediﬀerencesincellmembranefatty
acid composition,” The American Journal of Clinical Nutrition,
vol. 72, no. 5, pp. 1202–1205, 2000.
[6] S. Endres, R. Ghorbani, V. E. Kelley et al., “The eﬀect of
dietary supplementation with w3 polyunsaturated fatty acids
on the synthesis of interleukin -1 and tumor necrosis factor by
mononuclear cells,” The New England Journal of Medicine, vol.
320, no. 5, pp. 265–271, 1989.
[7] P. C. Calder, “Dietary fatty acids and lymphocyte functions,”
Proceedings of the Nutrition Society, vol. 57, no. 4, pp. 487–502,
1998.
[8] K. Fritsche, “Fatty acids as modulators of the immune
response,” Annual Review of Nutrition, vol. 26, pp. 45–73,
2006.
[9] S. M. Innis, “Maternal diet, length of gestation, and long-
chain polyunsaturatedfattyacidstatusof infantsat birth,”The
American Journal of Clinical Nutrition, vol. 70, no. 2, pp. 181–
182, 1999.
[10] S. J. Otto, A. C. van Houwelingen, A. Badart-Smook, and G.
Hornstra, “Comparison of the peripartum and postpartum
phospholipid polyunsaturated fatty acid proﬁles of lactating
and non-lactating women,” The American Journal of Clinical
Nutrition, vol. 73, no. 6, pp. 1074–1079, 2001.
[11] A. C. Houwelingen and G. Hornstra, “Relation between birth
order and the maternal and neonatal DHA status,” The
European Journal of Clinical Nutrition, vol. 51, no. 8, pp. 548–
553, 1997.
[12] A. P. Simopoulos, A. Leaf, and N. Salem, “Workshop on the
essentiality and recommended dietary intake for omega 6
and omega 3 fatty acids,” Journal of the American College of
Nutrition, vol. 18, no. 5, pp. 487–489, 1999.
[13] B. Koletzko, I. Cetin, and J. T. Brenna, “Dietary fat intakes
for pregnant and lactating women,” The British Journal of
Nutrition, vol. 98, no. 5, pp. 873–877, 2007.6 Mediators of Inﬂammation
[14] J. Denomme, K. D. Stark, and B. J. Holub, “Directly quan-
titated dietary w3 fatty acid intakes of pregnant Canadian
women are lower than current dietary recommendations,”
Journal of Nutrition, vol. 135, no. 2, pp. 206–211, 2005.
[15] N. M. Lewis, A. C. Widga, J. S. Buck, and A. M. Frederick,
“Survey of omega3 fatty acids in diets of Midwest low income
pregnant women,” Journal of Agromedicine, vol. 2, pp. 49–57,
1995.
[16] C. J. Field, C. A. Thomson, J. E. Van Aerde et al., “Lower
proportion of CD45R0+ cells and deﬁcient interleukin-10
production by formula-fed infants, compared with human-
fed, is corrected with supplementation of long-chain polyun-
saturated fatty acids,” Journal of Pediatric Gastroenterology and
Nutrition, vol. 31, no. 3, pp. 291–299, 2000.
[17] V. C. Mazurak, V. Lien, C. J. Field, S. D. Goruk, K. Pramuk,
andM.T.Clandinin,“Long-chainpolyunsaturatedfatsupple-
mentation in children with low docosahexaenoic acid intakes
alters immune phenotypes compared with placebo,” Journal
of Pediatric Gastroenterology and Nutrition,v o l .4 6 ,n o .5 ,p p .
570–579, 2008.
[18] S. Krauss-Etschmann, D. Hartl, P. Rzehak et al., “Decreased
cord blood IL-4, IL-13, and CCR4 and increased TGFβ levels
after ﬁsh oil supplementation of pregnant women,” Journal of
Allergy and Clinical Immunology, vol. 121, no. 2, pp. 464–470,
2008.
[19] R. A. Hoﬀm a n ,P .C .K u n g ,W .P .H a n s e n ,a n dG .G o l d s t e i n ,
“Simple and rapid measurement of human T lymphocytes
and their subclasses in peripheral blood,” Proceedings of the
National Academy of Sciences of the United States of America,
vol. 77, no. 8, pp. 4914–4917, 1980.
[20] L. J. Picker, M. K. Singh, Z. Zdraveski et al., “Direct demon-
stration of cytokine synthesis heterogeneity among human
memory/eﬀector T cells by ﬂow cytometry,” Blood, vol. 86, no.
4, pp. 1408–1419, 1995.
[21] C. A. Jolly, Y. H. Jiang, R. S. Chapkin, and D. N. McMurray,
“Dietary (n-3) polyunsaturated fatty acids suppress murine
lymphoproliferation, interleukin-2 secretion, and the forma-
tion of diacylglycerol and ceramide,” Journal of Nutrition, vol.
127, no. 1, pp. 37–43, 1997.
[22] S. N. Meydani, “Eﬀect of (n-3) polyunsaturated fatty acids on
cytokine production and their biologic function,” Nutrition,
vol. 12, no. 1, pp. S8–S14, 1996.
[23] A.Saedisomeolia,L.G.Wood,M.L.Garg,P.G.Gibson,andA.
B. Wark, “Anti-inﬂammatory eﬀects of long-chain n-3 PUFA
in rhinovirus-infected cultured airway epithelial cells,” The
British Journal of Nutrition, vol. 101, no. 4, pp. 533–540, 2009.
[24] N. Vaisman, Y. Zaruk, I. Shirazi, N. Kaysar, and V. Barak, “The
eﬀect of ﬁsh oil supplementation on cytokine production in
children,” The European Cytokine Network,v o l .1 6 ,n o .3 ,p p .
194–198, 2005.
[25] D. Wu, S. N. Meydani, M. Meydani, M. G. Hayek, P. Huth,
and R. J. Nicolosi, “Immunologic eﬀects of marine and
plant derived n-3 polyunsaturated fatty acids in non human
primates,” The American Journal of Clinical Nutrition, vol. 63,
no. 2, pp. 273–280, 1996.
[26] F. A. Wallace, E. A. Miles, and P. C. Calder, “Comparison of
the eﬀects of linseed oil and diﬀerent doses of ﬁsh oil on
mononuclear cell function in healthy human subjects,” The
British Journal of Nutrition, vol. 89, no. 5, pp. 679–689, 2003.
[27] J.W.C.SijbenandP.C.Calder,“Diﬀerentialimmunomodula-
tion with long chain n-3 PUFA in health and chronic disease,”
Proceedings of the Nutrition Society, vol. 66, no. 2, pp. 237–259,
2007.
[28] Q. Wang, X. N. Tang, and M. A. Yenari, “The inﬂammatory
response in stroke,” Journal of Neuroimmunology, vol. 184, no.
1-2, pp. 53–68, 2007.
[29] B. Saha, S. Jyothi Prasanna, B. Chandrasekar, and D. Nandi,
“Gene modulation and immunoregulatory roles of interferon
gamma,” Cytokine, vol. 50, no. 1, pp. 1–14, 2010.
[30] A. Eljaafari, Y. P. Li, and P. Miossec, “IFN-gamma, as secreted
during an alloresponse, induces diﬀerentiation of monocytes
into tolerogenic dendritic cells, resulting in FoxP3+ regulatory
Tc e l lp r o m o t i o n , ”Journal of Immunology, vol. 183, no. 5, pp.
2932–2945, 2009.
[31] I. Kryczek, S. Wei, W. Gong et al., “Cutting edge: IFN-gamma
enables APC to promote memory Th17 and abate Th1 cell
development,” Journal of Immunology, vol. 181, no. 9, pp.
5842–5846, 2008.